- Home
- BLK vs AMGN Comparison
BLK vs AMGN Comparison
Compare BLK & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLK
- AMGN
- Stock Information
- Founded
- BLK 1988
- AMGN 1980
- Country
- BLK United States
- AMGN United States
- Employees
- BLK N/A
- AMGN N/A
- Industry
- BLK Investment Bankers/Brokers/Service
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BLK Finance
- AMGN Health Care
- Exchange
- BLK Nasdaq
- AMGN Nasdaq
- Market Cap
- BLK 159.3B
- AMGN 141.6B
- IPO Year
- BLK 1999
- AMGN N/A
- Fundamental
- Price
- BLK $1,005.56
- AMGN $272.11
- Analyst Decision
- BLK Strong Buy
- AMGN Buy
- Analyst Count
- BLK 12
- AMGN 22
- Target Price
- BLK $1,111.83
- AMGN $324.05
- AVG Volume (30 Days)
- BLK 782.9K
- AMGN 3.5M
- Earning Date
- BLK 01-15-2025
- AMGN 02-04-2025
- Dividend Yield
- BLK 2.03%
- AMGN 3.50%
- EPS Growth
- BLK 15.06
- AMGN N/A
- EPS
- BLK 42.01
- AMGN 7.83
- Revenue
- BLK $20,407,000,000.00
- AMGN $32,534,000,000.00
- Revenue This Year
- BLK $14.18
- AMGN $20.07
- Revenue Next Year
- BLK N/A
- AMGN $3.59
- P/E Ratio
- BLK $23.92
- AMGN $34.74
- Revenue Growth
- BLK 14.27
- AMGN 21.25
- 52 Week Low
- BLK $745.55
- AMGN $253.30
- 52 Week High
- BLK $1,082.45
- AMGN $346.85
- Technical
- Relative Strength Index (RSI)
- BLK 48.57
- AMGN 54.19
- Support Level
- BLK $982.18
- AMGN $267.15
- Resistance Level
- BLK $1,025.45
- AMGN $272.82
- Average True Range (ATR)
- BLK 20.59
- AMGN 4.68
- MACD
- BLK -1.28
- AMGN 2.37
- Stochastic Oscillator
- BLK 55.50
- AMGN 75.60
About BLK BlackRock Inc.
BlackRock is the largest asset manager in the world, with $11.475 trillion in assets under management at the end of September 2024. Its product mix is fairly diverse, with 55% of managed assets in equity strategies, 26% in fixed income, 9% in multi-asset classes, 7% in money market funds, and 3% in alternatives. Passive strategies account for around two thirds of long-term AUM, with the company's ETF platform maintaining a leading market share domestically and on a global basis. Product distribution is weighted more toward institutional clients, which by our calculations account for around 80% of AUM. BlackRock is geographically diverse, with clients in more than 100 countries and more than one third of managed assets coming from investors domiciled outside the US and Canada.
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.